New task order under IDIQ contract HHSF223201610004I entitled, "a randomized, open label, two treatment, four period, single dose, fully replicate, crossover bioequivalence (be) study of tacrolimus…

Ended Awarded Last action

Contract number
75F40120F19005
Awardee
Awarding agency
Obligated
$1,845,195

Award facts

Contract value 100% obligated
$1,845,195.00 Current and potential, with all options
Completion date 100% complete
Current and potential, with all options
Set-aside
No set-aside
Competition
Full and Open Competition Negotiated Proposal / Quote
Pricing
Firm Fixed Price
Place of performance
Columbia, MO 65201, USA

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Close Out P00005 -$1
Change Order P00004 · Modification to add additional funding to cover unforeseen cost increases in subject recruitment due to the covid-19 pandemic. $19,744
Other Administrative Action P00003 · Modification to extend the period of performance end date to 05/31/2022. A revised deliverable table is attached $0
Supplemental Agreement for work within scope P00002 · Modification to revised the human subject language in the SOW and extend the period of performance end date to 01/03/2022. $0
Supplemental Agreement for work within scope P00001 · Modification to add four(4) additional subjects, extend the period of performance and to add new measures to assure subject safety due to covid-19 under task… $326,037
Original award $1,499,415

About this award

Written by GovTribe AI ·

The U.S. Food and Drug Administration (FDA) awarded a $1,845,195.00 firm fixed price delivery order contract to Biopharma Services USA Inc., a foreign-owned small disadvantaged business, to conduct a randomized, open-label, two-treatment, four-period, single-dose, fully replicate, crossover bioequivalence (BE) study of tacrolimus capsules 5 mg. This task order was issued under an Indefinite Delivery/Indefinite Quantity (IDIQ) contract with the ID HHSF223201610004I. The contract has a May 31, 2022 ultimate completion date and is part of the FDA's program for in vivo study of generic drug products in human subjects. The contract did not use a set-aside designation.

Description

As the agency reported it.

New task order under IDIQ contract HHSF223201610004I entitled, "a randomized, open label, two treatment, four period, single dose, fully replicate, crossover bioequivalence (be) study of tacrolimus capsules 5 MG"

Quick answers

Who was awarded contract 75F40120F19005?

75F40120F19005 was awarded to Biopharma Services USA by Food and Drug Administration (Department of Health and Human Services) on March 10, 2020.

How much is contract 75F40120F19005 worth?

The government has obligated $1,845,195 on 75F40120F19005.

Is contract 75F40120F19005 an order under another contract?

Yes. 75F40120F19005 is a delivery order under HHSF223201610004I, an indefinite delivery contract.

Was contract 75F40120F19005 competed?

The extent of competition for 75F40120F19005 was full and open competition.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award
Try for free Login